HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IRWD
Ironwood Pharmaceuticals, Inc.
IRWD's fundamentals are mixed, but it looks cheap: trading at 5.4x earnings, less than half its usual 12x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IRWD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
IRWD's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IRWD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.6x | $4.85 | — |
| Cheap | 4x | $3.62 | -25% |
| Current | 5.4x | $4.85 | — |
| Fair | 12x | $10.94 | +125% |
| Expensive | 24x | $21.19 | +337% |
Historical ranges are pointers, not guarantees.
IRWD's PE is in its cheap range at 5.4x. If earnings grow as analysts expect, today's price would be 3.6x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IRWD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
IRWD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IRWD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.37 | +52% |
| Q3 2026 | $0.90 | +500% |
| Q2 2026 | $0.77 | +$0.83 |
| Q1 2026 | $0.60 | +$0.81 |
| Q4 2025 | $0.13 | +$0.14 |
| Q3 2025 | $0.15 | +$0.18 |
| Q2 2025 | -$0.06 | -250% |
| Q1 2025 | -$0.21 | +$6.58 |
| Q4 2024 | -$0.01 | +$6.50 |
IRWD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IRWD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IRWD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $133M | +9% |
| Q2 2026 | $113M | +33% |
| Q1 2026 | $106.5M | +159% |
| Q4 2025 | $47.7M | -47% |
| Q3 2025 | $122.1M | +33% |
| Q2 2025 | $85.2M | -9.7% |
| Q1 2025 | $41.1M | -45% |
| Q4 2024 | $90.5M | -23% |
IRWD's revenue is growing: $133M last quarter, up 9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 70% | +8.2 points |
| Q2 2026 | 70% | +17 points |
| Q1 2026 | 68% | +139 points |
| Q4 2025 | 14% | -21 points |
| Q3 2025 | 62% | +34 points |
| Q2 2025 | 53% | +27 points |
| Q1 2025 | -71% | -86 points |
| Q4 2024 | 35% | +2.8 points |
IRWD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
IRWD has the stronger cash trend. Its trailing FCF is down 24% versus its history, compared with HIMS at down 84%.
IRWD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $74.6M | +390% |
| Q3 2025 | $47.6M | +382% |
| Q2 2025 | -$15.1M | -145% |
| Q1 2025 | $19.9M | -56% |
| Q4 2024 | $15.2M | -57% |
| Q3 2024 | $9.9M | -70% |
| Q2 2024 | $33.4M | -4.5% |
| Q1 2024 | $44.9M | -44% |
IRWD still generates free cash flow, though less than at its 2023 peak: $127M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IRWD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IRWD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +998K shares |
| 1 year | -5.4% | -9.6M shares |
| 3 years | -10% | -18.7M shares |
| 5 years | +1.8% | +2.9M shares |
| Available history | +7.8% | +12.2M shares |
IRWD has 168M diluted shares, down 5.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q1 2022 | $92.5M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IRWD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.9x | Very low |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.7x | Healthy |
| Q4 2024 | 3.1x | Elevated |
IRWD's net debt is less than a year of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IRWD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.6 | Neutral |
| Stochastic | 61.2 | Neutral |
IRWD's weekly RSI is 62 (neutral) and its Stochastic is 61 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IRWD PE vs Healthcare Sector
| Metric | IRWD | Sector median | Relative |
|---|---|---|---|
| PE | 5.4x | 26x | 79% below |
| PE % | 25 | 29 | 4 pts below |
IRWD is trading at 5.4x earnings, a 79% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IRWD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.91 | 24% above |
| 20 week MA | $4.08 | 19% above |
| 50 week MA | $3.95 | 23% above |
| 100 week MA | $2.81 | 73% above |
| 200 week MA | $5.79 | 16% below |
IRWD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IRWD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.5 | $11.7 | -13% |
| 2021 | $11.7 | $11.9 | +1.3% |
| 2022 | $11.9 | $12.4 | +4.3% |
| 2023 | $12.4 | $11.4 | -7.6% |
| 2024 | $11.4 | $4.45 | -61% |
| 2025 | $4.45 | $3.20 | -28% |
| 2026 YTD | $3.20 | $4.85 | +52% |
IRWD has the edge over HIMS on returns for 2026, with the stronger performance.